Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
B- Exenatide twice daily · 1 trial · 1 indication
Change in HbA1c from Baseline Visit 3 (Day 1) to study termination (Day 28)
| Arm | Type | Description |
|---|---|---|
| A1 - Placebo 0.04 mL twice daily | PLACEBO_COMPARATOR | - |
| A2 - Placebo 0.04 mL once daily | PLACEBO_COMPARATOR | - |
| A3 - Placebo 0.08 mL once daily | PLACEBO_COMPARATOR | - |
| B - Exenatide 10 mcg twice daily | EXPERIMENTAL | - |
| C - Exenatide 10 mcg once daily | EXPERIMENTAL | - |
| D - Exenatide 20 mcg once daily | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo 0.04 mL twice daily | DRUG | Subcutaneously injected, 0.04 mL, twice daily |
| Placebo 0.04 mL once daily | DRUG | Subcutaneously injected, 0.04 mL, once daily |
| Placebo 0.08 mL once daily | DRUG | Subcutaneously injected, 0.08 mL, once daily |
| B - Exenatide 10 mcg twice daily | DRUG | Subcutaneously injected, 10 mcg (0.04 mL), twice daily |
| C - Exenatide 10 mcg once daily | DRUG | Subcutaneously injected, 10 mcg (0.04 mL), once daily |
| Exenatide 20 mcg once daily | DRUG | Subcutaneously injected, 20 mcg (0.08 mL), once daily |
Inclusion Criteria: * Subject has type 2 diabetes mellitus treated with diet and exercise modification alone or in combination with one oral antidiabetic agent for no longer than 4 years. Exclusion Criteria: * Subject has a clinically significant history or presence of any of the following condit...
B- Exenatide twice daily is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for the treatment of type 2 diabetes mellitus. It is being studied as monotherapy to assess its effect on glucose control in adults with the condition. The program is in Phase 2 clinical development.
B- Exenatide twice daily is being evaluated for glucose control in adults with type 2 diabetes mellitus. A completed Phase 2 trial, NCT00085969, studied it as monotherapy in subjects with the condition, measuring its effect on glycemic control. It is an investigational agent and is not approved for this use.
B- Exenatide twice daily is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating the drug in type 2 diabetes mellitus.
B- Exenatide twice daily is in Phase 2 clinical development. One Phase 2 trial has been completed, and no trials are currently active. The drug remains investigational and has not been approved for any indication.
B- Exenatide twice daily has been studied in one completed Phase 2 trial, NCT00085969, titled Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus. The trial enrolled 99 participants in the United States, was randomized, double-blind, and placebo-controlled, and included adults aged 18 years and older.